What are ADC's

Our services

ADC Review
is made possible by:

NCT00038805 (Clinical Trial / Gemtuzumab Ozogamicin)

Study Title
Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) (NCT00038805)

Trial Description
Primary Objective:

  • To determine the safety and maximum tolerated dose of gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) as part of an intensive but nonmyeloablative preparative regimen in older or medically infirm patients undergoing mini-allogeneic peripheral blood stem cell transplantation

Secondary Objectives:

  • To evaluate response rates, engraftment kinetics and degree of chimerism achievable with this strategy.
  • To evaluate disease-free and overall survival and relapse rates.
  • To evaluate the need and ability to give multiple cycles of gemtuzumab ozogamicin plus FA and mobilized DLI in patients not achieving complete remission.

This trial is sponsored by M.D. Anderson Cancer Center. [1]

Study Data

  • Condition: Leukemia
  • Interventions:
  • Phase: II & III
  • Enrollment: 3
  • Start: May 2001
  • Completion: November 2004
  • Last verified: July 2012

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 21, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar